Download PDF
Nephrologie aktuell 2024; 28(05): 222-229
DOI: 10.1055/a-2254-7940
Schwerpunkt
Dialyse

Nierenersatztherapie in der Intensivmedizin

Spezialindikation: früher Beginn und erweiterter Organersatz
Philipp Enghard
1   Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin der Charité – Universitätsmedizin Berlin, Berlin
,
Anne Krüger
1   Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin der Charité – Universitätsmedizin Berlin, Berlin
,
Achim Jörres
2   Medizinische Klinik I Nephrologie, Transplantationsmedizin und internistische Intensivmedizin, Kliniken der Stadt Köln, Krankenhaus Merheim, Klinikum der Universität Witten/Herdecke, Merheim
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Neben den klassischen Indikationen für die Nierenersatztherapie (NET) gibt es eine Reihe von Spezialindikationen sowie die Möglichkeit, mit Adsorbern oder speziellen Verfahren gezielt die Homöostase in verschiedenen Krankheitsbildern wiederherzustellen. Das macht die NET auf Intensivstation zu einem spannenden und dynamischen Feld mit vielfältigen Einsatzmöglichkeiten. Aktuell fehlt für die meisten Indikationen allerdings noch eine gute Datenbasis für die Anwendung der entsprechenden Verfahren, sodass derzeit kein Einsatz in der klinischen Routine (außerhalb klinischer Studien) empfohlen werden kann.



Publication History

Article published online:
25 June 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Adeyinka A, Bashir K. Tumor Lysis Syndrome. In: StatPearls Publishing 2023 [cited 2023 Dec 5]. Im Internet. www.ncbi.nlm.nih.gov/books/NBK518985 Stand: 18.03.2024
    PubMedGoogle Scholar
  • 2 Arnaud M, Loiselle M, Vaganay C. et al Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms. J Am Soc Nephrol 2022; 33: 1154-1171
    CrossrefPubMedGoogle Scholar
  • 3 Anderson A, Shoulders L, James V. et al Benefit of continuous kidney replacement therapy for managing tumor lysis syndrome in children with hematologic malignancies. Front Oncol 2023; 13: 1234677
    CrossrefPubMedGoogle Scholar
  • 4 Casserly B, Phillips GS, Schorr C. et al Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med 2015; 43: 567-573
    CrossrefPubMedGoogle Scholar
  • 5 Vincent JL, Bakker J. Blood lactate levels in sepsis: in 8 questions. Curr Opin Crit Care 2021; 27: 298-302
    CrossrefPubMedGoogle Scholar
  • 6 Reis T, Ronco F, Ostermann M. Diuretics and Ultrafiltration in Heart Failure. Cardiorenal Med 2023; 13: 56-65
    CrossrefPubMedGoogle Scholar
  • 7 Cullis B, Al-Hwiesh A, Kilonzo K. et al ISPD guidelines for peritoneal dialysis in acute kidney injury: 2020 update (adults). Perit Dial Int 2021; 41: 15-31
    CrossrefPubMedGoogle Scholar
  • 8 Al Sahlawi M, Ponce D, Charytan DM. et al Peritoneal Dialysis in Critically Ill Patients: Time for a Critical Reevaluation?. Clin J Am Soc Nephrol 2023; 18: 512-520
    CrossrefPubMedGoogle Scholar
  • 9 Honore PM, Clark W. Preliminary results of the HICOSS study. Proc 10th WFSCICCM 2009. 2009 Florenz (Italien)
    PubMedGoogle Scholar
  • 10 Joannes-Boyau O, Honoré PM, Perez P. et al High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013; 39: 1535-1546
    CrossrefPubMedGoogle Scholar
  • 11 Cruz BA, Ramanoelina J, Mahr A. et al Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology (Oxford) 2003; 42: 1183-1188
    CrossrefPubMedGoogle Scholar
  • 12 Payen DM, Guilhot J, Launey Y. et al Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015; 41: 975-984
    CrossrefPubMedGoogle Scholar
  • 13 Dellinger RP, Bagshaw SM, Antonelli M. et al Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA 2018; 320: 1455-1463
    CrossrefPubMedGoogle Scholar
  • 14 Eden G, Schmidt JJ, Büttner S. et al Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Crit Care 2022; 26: 181
    CrossrefPubMedGoogle Scholar
  • 15 Andermatt R, Bloemberg GV, Ganter CC. et al Elimination of Herpes Simplex Virus-2 and Epstein-Barr Virus With Seraph 100 Microbind Affinity Blood Filter and Therapeutic Plasma Exchange: An Explorative Study in a Patient With Acute Liver Failure. Crit Care Explor 2022; 04: e0745
    CrossrefPubMedGoogle Scholar
  • 16 Friesecke S, Stecher SS, Gross S. et al Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs 2017; 20: 252-259
    CrossrefPubMedGoogle Scholar
  • 17 Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care 2019; 23: 317
    CrossrefPubMedGoogle Scholar
  • 18 Wendel Garcia PD, Hilty MP, Held U. et al Cytokine adsorption in severe, refractory septic shock. Intensive Care Med 2021; 47: 1334-1336
    CrossrefPubMedGoogle Scholar
  • 19 Becker S, Lang H, Vollmer Barbosa C. et al Efficacy of CytoSorb®: a systematic review and meta-analysis. Crit Care 2023; 27: 215
    CrossrefPubMedGoogle Scholar
  • 20 Rimmer E, Houston BL, Kumar A. et al The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care 2014; 18: 699
    CrossrefPubMedGoogle Scholar
  • 21 Knaup H, Stahl K, Schmidt BMW. et al Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 2018; 22: 285
    CrossrefPubMedGoogle Scholar
  • 22 David S, Bode C, Putensen C. et al EXCHANGE study group. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med 2021; 47: 352-354
    CrossrefPubMedGoogle Scholar
  • 23 David S, Bode C, Stahl K. EXCHANGE-2 Study group. EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock-a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial. Trials 2023; 24: 277
    CrossrefPubMedGoogle Scholar
  • 24 Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361: 62-72
    CrossrefPubMedGoogle Scholar
  • 25 Albrecht F, Schunk S, Fuchs M. et al Rapid and Effective Elimination of Myoglobin with CytoSorb® Hemoadsorber in Patients with Severe Rhabdomyolysis. Blood Purif 2024; 53: 88-95
    CrossrefPubMedGoogle Scholar
  • 26 Gräfe C, Liebchen U, Greimel A. et al The effect of cytosorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis. Ren Fail 2023; 45: 2259231
    CrossrefPubMedGoogle Scholar
  • 27 Huber W, Ruiz de Garibay AP. Options in extracorporeal support of multiple organ failure. Med Klin Intensivmed Notfmed 2020; 115 (Suppl. 01) 28-36
    CrossrefPubMedGoogle Scholar
  • 28 Thompson Bastin ML, Stromberg AJ, Nerusu SN. et al Association of Phosphate-Containing versus Phosphate-Free Solutions on Ventilator Days in Patients Requiring Continuous Kidney Replacement Therapy. Clin J Am Soc Nephrol 2022; 17: 634-642
    CrossrefPubMedGoogle Scholar
  • 29 Wallon G, Guth C, Guichon C. et al Extracorporeal Albumin Dialysis in Liver Failure with MARS and SPAD: A Randomized Crossover Trial. Blood Purif 2022; 51: 243-250
    CrossrefPubMedGoogle Scholar
  • 30 Sauer IM, Goetz M, Steffen I. et al In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 2004; 39: 1408-1414
    CrossrefPubMedGoogle Scholar
  • 31 Mitzner SR, Stange J, Klammt S. et al Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J 2009; 55: 498-502
    CrossrefPubMedGoogle Scholar
  • 32 Huber W, Lorenz G, Heilmaier M. et al Extracorporeal multiorgan support including CO 2 -removal with the ADVanced Organ Support (ADVOS) system for COVID-19: A case report. Int J Artif Organs 2021; 44: 288-294
    CrossrefPubMedGoogle Scholar
  • 33 Larsen FS, Schmidt LE, Bernsmeier C. et al High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol 2016; 64: 69-78
    CrossrefPubMedGoogle Scholar
  • 34 Calabrò MG, Febres D, Recca G. et al Blood Purification With CytoSorb in Critically Ill Patients: Single-Center Preliminary Experience. Artif Organs 2019; 43: 189-194
    CrossrefPubMedGoogle Scholar
  • 35 Scharf C, Liebchen U, Paal M. et al Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study. Sci Rep 2021; 11: 10190
    CrossrefPubMedGoogle Scholar
  • 36 Saliba F, Bañares R, Larsen FS. et al Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts. Intensive Care Med 2022; 48: 1352-1367
    CrossrefPubMedGoogle Scholar
  • 37 Falkensteiner C, Kortgen A, Leonhardt J. et al Comparison of albumin dialysis devices molecular adsorbent recirculating system and ADVANCED Organ Support system in critically ill patients with liver failure—A retrospective analysis. Ther Apher Dial 2021; 25: 225-236
    CrossrefPubMedGoogle Scholar
  • 38 Kortgen A, Rauchfuss F, Götz M. et al Albumin Dialysis in Liver Failure: Comparison of Molecular Adsorbent Recirculating System and Single Pass Albumin Dialysis--A Retrospective Analysis. Ther Apher Dial 2009; 13: 419-425
    CrossrefPubMedGoogle Scholar
  • 39 Fuhrmann V, Perez Ruiz De Garibay A, Faltlhauser A. et al Registry on extracorporeal multiple organ support with the advanced organ support (ADVOS) system: 2-year interim analysis. Medicine (Baltimore) 2021; 100: e24653 al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19: 349
    CrossrefPubMedGoogle Scholar
  • 40 Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload?. Crit Care 2017; 21: 281
    CrossrefPubMedGoogle Scholar
  • 41 Husain-Syed F, Emlet DR, Wilhelm J. et al Effects of preoperative high-oral protein loading on short- and long-term renal outcomes following cardiac surgery: a cohort study. J Transl Med 2022; 20: 204
    CrossrefPubMedGoogle Scholar
  • 42 Worku B, Khin S, Gaudino M. et al Renal replacement therapy in patients on extracorporeal membrane oxygenation support: Who and how. Int J Artif Organs 2021; 44: 531-538
    CrossrefPubMedGoogle Scholar
  • 43 Schmidt M, Jaber S, Zogheib E. et al Feasibility and safety of low-flow extracorporeal CO2 removal managed with a renal replacement platform to enhance lung-protective ventilation of patients with mild-to-moderate ARDS. Crit Care 2018; 22: 122
    CrossrefPubMedGoogle Scholar
  • 44 Nentwich J, Wichmann D, Kluge S. et al Low-flow CO2 removal in combination with renal replacement therapy effectively reduces ventilation requirements in hypercapnic patients: a pilot study. Ann Intensive Care 2019; 09: 3
    CrossrefPubMedGoogle Scholar
  • 45 Allescher J, Rasch S, Wiessner JR. et al Extracorporeal carbon dioxide removal with the Advanced Organ Support system in critically ill COVID-19 patients. Artif Organs 2021; 45: 1522-1532
    CrossrefPubMedGoogle Scholar